X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/07/2841977/0/en/Oxford-BioTherapeutics-Announces-Launch-of-Enhanced-Discovery-Platform-OGAP-Verify-at-World-ADC-Conference-2024.html
https://www.globenewswire.com//news-release/2024/01/18/2811280/0/en/Oxford-BioTherapeutics-Announces-First-Patient-Dosed-with-OBT076-in-Phase-1b-Trial-in-Adenoid-Cystic-Carcinomas-of-the-Head-and-Neck.html
https://www.globenewswire.com//news-release/2023/11/29/2787760/0/en/Oxford-BioTherapeutics-Announces-Partner-Boehringer-Ingelheim-Received-U-S-FDA-Fast-Track-Designation-for-BI-764532-for-the-Potential-Treatment-of-Advanced-or-Metastatic-Large-Cell.html
https://www.globenewswire.com//news-release/2023/10/24/2765740/0/en/Oxford-BioTherapeutics-Announces-Partner-Boehringer-Ingelheim-Dosed-First-Patient-in-Phase-2-Trial-with-BI-764532-in-Small-Cell-Lung-Cancer-and-other-Neuroendocrine-Cancers.html
https://www.globenewswire.com//news-release/2023/10/11/2758089/0/en/Oxford-BioTherapeutics-Relocates-UK-Headquarters-to-Strategic-and-Cutting-Edge-R-D-Location-at-The-Oxford-Science-Park-to-Accelerate-Development-of-its-Immuno-Oncology-and-ADC-Base.html
https://www.globenewswire.com//news-release/2023/10/03/2753300/0/en/Oxford-BioTherapeutics-Announces-Partner-Boehringer-Ingelheim-Received-U-S-FDA-Fast-Track-Designation-for-BI-764532-for-the-Treatment-of-Extensive-Stage-Small-Cell-Lung-Cancer-and-.html
https://www.globenewswire.com/news-release/2023/07/05/2699287/0/en/Oxford-BioTherapeutics-Initiates-Phase-Ib-Clinical-Trial-for-OBT076-in-Patients-with-Advanced-Solid-Tumors-by-Dosing-First-Patient-in-Combination-with-CPI-Balstilimab-in-Europe.html
https://www.globenewswire.com/news-release/2023/05/25/2675848/0/en/Oxford-BioTherapeutics-and-Boehringer-Ingelheim-Agree-on-2-Year-Extension-to-their-Second-Multi-Year-Collaboration-in-Cancer-Immunology.html
https://endpts.com/boehringer-ingelheim-extends-2020-collab-with-oxford-biotherapeutics-european-biotechs-claim-positive-phi-i-o-data/
https://www.globenewswire.com/news-release/2023/04/19/2649731/0/en/Oxford-BioTherapeutics-announces-Phase-1b-trial-in-collaboration-with-GORTEC-to-investigate-OBT076-in-Adenoid-Cystic-Carcinoma-ACC-of-the-head-and-neck.html
Market Place
Share 
